Beranda › Liposarcoma › Massachusetts
Uji klinis Liposarcoma di Massachusetts
7 studi untuk Liposarcoma mencari peserta di lokasi di Massachusetts.
Kota di Massachusetts
Teks studi resmi (Bahasa Inggris)
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06422806A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
- Investigative Site, Boston
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06881992Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
- Dana-Farber/Harvard Cancer Center, Boston
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT04031677Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
- Dana-Farber Cancer Institute, Boston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT05711615STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
- Dana Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT06975293NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
- Dana Farber Cancer Institute, Boston
Menerima pesertaFase 1/2
Hingga usia 30 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT06239272Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
- Brigham and Women's Hospital, Boston
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT07377747Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.